Eli Lilly’s market share in India’s GLP-1 weight-loss drug sector has declined from 61% to 56% in March, while rival Novo Nordisk maintained its 25% share, according to Pharmarack data. This shift comes as a wave of lower-priced generics, following the expiration of the semaglutide patent, floods the market. The competitive landscape is intensifying, with 13 Indian generic manufacturers launching 26 brands of semaglutide, which is prescribed for weight loss and diabetes management.
This erosion of Eli Lilly’s market position is significant given India’s vast population of 100 million diabetics and a growing obesity crisis. The price war initiated by Novo Nordisk, which has cut prices of its semaglutide products by up to 48%, further pressures Eli Lilly’s higher-priced tirzepatide offerings. Analysts suggest that as generics gain traction, Eli Lilly’s more expensive options may increasingly appeal only to wealthier patients seeking effective weight-loss solutions.
Market professionals should note that the competitive dynamics in India’s GLP-1 market are likely to favor generic manufacturers, with demand shifting towards affordability. As the market expands, attention will be crucial on which players emerge as leaders amid this evolving landscape.
Source: cnbc.com